GLP-1 RAs and dual agonists maintain metabolic efficacy in elderly populations
Slower gastric emptying: Food moves through the digestive system more slowly, increasing the sensation of fullness after meals
Although the study focused on autoimmune patients with diabetes, the findings highlight the potential of GLP-1 receptor agonists in managing cardiovascular risk in the broader autoimmune population
Key Highlights: 48 PSGs for products with no approved ANDAs (25 complex products) 39 PSGs for complex products (6 new, 33 revised) Therapies for COPD, opioid overdose, type 2 diabetes, major depressive disorder, and more Notable PSGs: Ensifentrine inhalation suspension (COPD, RLD: OHTUVAYRE) Naloxone hydrochloride nasal spray (Opioid overdose, RLD: REZENOPY) Semaglutide oral tablet (Type 2 diabetes, RLD: RYBELSUS) Trazodone hydrochloride ER oral tablet (MDD, RLD: OLEPTRO) Link : By publishing PSGs, FDA continues to promote innovation in generic development while advancing public health and patient access to cost-effective medicines